Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney shield? new trial tests citrus compound for chemo patients

NCT ID NCT07598214

Symptom relief Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of diosmin and hesperidin, natural compounds found in citrus fruits, can protect the kidneys of cancer patients receiving platinum-based chemotherapy. One hundred adults with confirmed cancer will take the supplement alongside their chemo to see if it reduces kidney damage. The goal is to ease a common side effect, not to treat the cancer itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
diosmin/hesperidin combination
What this could lead to
If it works, this could offer a simple way to reduce kidney damage from platinum chemotherapy, helping cancer patients tolerate treatment better.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply widely. The supplement might not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy. Exclusion Criteria: * -History of allergic reactions attributed to drugs in the study. * Pregnant women. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Cancer patients with impaired renal function (creatinine clearance \< 50 mL/min) * Preexisting hearing loss. * Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer patients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine

    RECRUITING

    Banī Suwayf, 0000, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.